CENTOGENE N.V. (CNTG): Price and Financial Metrics
CNTG Price/Volume Stats
| Current price | $0.49 | 52-week high | $1.98 |
| Prev. close | $0.48 | 52-week low | $0.43 |
| Day low | $0.45 | Volume | 6,900 |
| Day high | $0.49 | Avg. volume | 49,075 |
| 50-day MA | $0.67 | Dividend yield | N/A |
| 200-day MA | $1.02 | Market Cap | 13.24M |
CNTG Stock Price Chart Interactive Chart >
CENTOGENE N.V. (CNTG) Company Bio
Centogene NV is a commercial-stage company. It focuses on rare diseases that transform real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. It operates through the following two segments: Pharmaceutical and Diagnostics. The Pharmaceutical segment provides services to pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery and patient monitoring. The Diagnostics segment provides targeted genetic sequencing and diagnostics services. The company was founded by Arndt Rolf and Christoph Ehlers in 2006 and is headquartered in Rostock, Denmark.
Latest CNTG News From Around the Web
Below are the latest news stories about CENTOGENE NV that investors may wish to consider to help them evaluate CNTG as an investment opportunity.
CENTOGENE Announces Voting Results of Extraordinary General MeetingCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 19, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the voting results of the Company’s Extraordinary General Meeting. All voting items on the agenda, which included the adoption of Dutch statutory annual accounts for the financial year ended December 31, 2022, were passed by the requisite majority. Peer Schatz, Chairman |
CENTOGENE’s Frontotemporal Dementia (FTD) Genetic Study, EFRONT, Reaches Initial Patient Enrollment MilestoneCAMBRIDGE, Mass. and ROSTOCK, Germany, and BERLIN, Dec. 13, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the Company reached its initial recruitment and genetic testing milestone in the observational EFRONT Study, being conducted to advance the genetic understanding of frontotemporal dementia (FTD). The EFRONT Study has been conducted with support from Alector, a clinical |
CENTOGENE and Lifera, a Public Investment Fund (PIF) Company, Complete Strategic Joint Venture TransactionLifera Omics, newly formed Joint Venture (JV) to be based in Riyadh, Saudi Arabia, provides state-of-the-art genomic and multiomic testing services to patients, health systems, biopharma clients, and research institutions across the Gulf Cooperation Council (GCC) region CENTOGENE to receive an additional $10 million upfront JV milestone payment, following an initial $30 million investment from Lifera. Company eligible for additional performance-related milestone payments and revenue-based royalt |
CENTOGENE, University College London, and Global Team of Researchers Discover Gene Associated With New Neurodevelopmental Disease Linked to Early-Onset Dystonia and ParkinsonismResults From Landmark Study Published in Brain JournalCollaborative research initiative leveraged CENTOGENE’s Whole Exome Sequencing (WES) to reveal disease-causing gene called ACBD6 (Acyl-CoA Binding Domain Containing 6) Over seven years, a total of 45 affected individuals from 29 independent families in Southeast Asia, Central Asia, the Middle East, Europe, and North and South America have been identified Study guides further research for potential treatments, including genetic causes and path |
CENTOGENE Expands Multiomic Diagnostic Portfolio With Newly-Launched Transcriptomic OfferingIncorporating RNA sequencing provides better diagnostics to enable a more complete understanding of disease biologyCAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Oct. 10, 2023 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life science partner for data-driven answers in rare and neurodegenerative diseases, today announced the expansion of MOx, the Company’s multiomic diagnostic portfolio, now incorporating cutting-edge transcriptomic analysis. CENTOGENE’s MOx 2.0 is a single |
CNTG Price Returns
| 1-mo | -28.99% |
| 3-mo | -57.02% |
| 6-mo | -53.55% |
| 1-year | -59.50% |
| 3-year | -95.73% |
| 5-year | N/A |
| YTD | -59.17% |
| 2023 | 29.03% |
| 2022 | -82.21% |
| 2021 | -51.50% |
| 2020 | 7.05% |
| 2019 | N/A |
Loading social stream, please wait...